Cartilage and Osteoarthritis

¡ ¡
¡ Methods in Molecular Medicine āĻŦāχ 100 ¡ Springer Science & Business Media
āχ-āĻŦ⧁āĻ•
358
āĻĒ⧃āĻˇā§āĻ āĻž
āϰ⧇āϟāĻŋāĻ‚ āĻ“ āϰāĻŋāĻ­āĻŋāω āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻšā§ŸāύāĻŋ  āφāϰāĻ“ āϜāĻžāύ⧁āύ

āĻāχ āχ-āĻŦ⧁āϕ⧇āϰ āĻŦāĻŋāĻˇā§Ÿā§‡

Osteoarthritis (OA), the most common form of arthritis, is generally characterized by a slowly progressive degeneration of articular cartilage, particularly in the weight-bearing joints. It has a stronger prevalence in women, and its incidence increases with age. OA is a major and growing health concern in developed countries, owing to steadily increasing life expectancy and the demand for better quality of life. Because of its chronic nature and nonfatal outcome, OA affects the growing population of the elderly over an increasing time span. Moreover, despite its relatively benign character, OA is one of the most disabling diseases; it is responsible for increasing financial and social burdens in terms of medical treatments, forced inactivity, loss of mobility, and dependence. Despite a growing awareness of OA as a medical problem that has yet to reach its maximum impact on society, there is a surprising absence of effective medical treatments beyond pain control and surgery. So far, only symptom-modifying drugs are available, while there remains a major demand for disease-modifying treatments of proven clinical efficacy. This demand will hopefully be met in the future by some of the drugs that have been pressed into development and are now at different stages of clinical investigation. Nevertheless, the current lack of effective treatments reflects a still insufficient knowledge of cartilage with respect to its metabolism, interactions with other joint tissues, and causes and mechanisms (possibly of very different nature) leading to failure of its turnover.

āχ-āĻŦ⧁āϕ⧇ āϰ⧇āϟāĻŋāĻ‚ āĻĻāĻŋāύ

āφāĻĒāύāĻžāϰ āĻŽāϤāĻžāĻŽāϤ āϜāĻžāύāĻžāύāĨ¤

āĻĒāĻ āύ āϤāĻĨā§āϝ

āĻ¸ā§āĻŽāĻžāĻ°ā§āϟāĻĢā§‹āύ āĻāĻŦāĻ‚ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ
Android āĻāĻŦāĻ‚ iPad/iPhone āĻāϰ āϜāĻ¨ā§āϝ Google Play āĻŦāχ āĻ…ā§āϝāĻžāĻĒ āχāύāĻ¸ā§āϟāϞ āĻ•āϰ⧁āύāĨ¤ āĻāϟāĻŋ āφāĻĒāύāĻžāϰ āĻ…ā§āϝāĻžāĻ•āĻžāωāĻ¨ā§āĻŸā§‡āϰ āϏāĻžāĻĨ⧇ āĻ…āĻŸā§‹āĻŽā§‡āϟāĻŋāĻ• āϏāĻŋāĻ™ā§āĻ• āĻšā§Ÿ āĻ“ āφāĻĒāύāĻŋ āĻ…āύāϞāĻžāχāύ āĻŦāĻž āĻ…āĻĢāϞāĻžāχāύ āϝāĻžāχ āĻĨāĻžāϕ⧁āύ āύāĻž āϕ⧇āύ āφāĻĒāύāĻžāϕ⧇ āĻĒ⧜āϤ⧇ āĻĻā§‡ā§ŸāĨ¤
āĻ˛ā§āϝāĻžāĻĒāϟāĻĒ āĻ“ āĻ•āĻŽā§āĻĒāĻŋāωāϟāĻžāϰ
Google Play āĻĨ⧇āϕ⧇ āϕ⧇āύāĻž āĻ…āĻĄāĻŋāĻ“āĻŦ⧁āĻ• āφāĻĒāύāĻŋ āĻ•āĻŽā§āĻĒāĻŋāωāϟāĻžāϰ⧇āϰ āĻ“ā§Ÿā§‡āĻŦ āĻŦā§āϰāĻžāωāϜāĻžāϰ⧇ āĻļ⧁āύāϤ⧇ āĻĒāĻžāϰ⧇āύāĨ¤
eReader āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻĄāĻŋāĻ­āĻžāχāϏ
Kobo eReaders-āĻāϰ āĻŽāϤ⧋ e-ink āĻĄāĻŋāĻ­āĻžāχāϏ⧇ āĻĒāĻĄāĻŧāϤ⧇, āφāĻĒāύāĻžāϕ⧇ āĻāĻ•āϟāĻŋ āĻĢāĻžāχāϞ āĻĄāĻžāωāύāϞ⧋āĻĄ āĻ“ āφāĻĒāύāĻžāϰ āĻĄāĻŋāĻ­āĻžāχāϏ⧇ āĻŸā§āϰāĻžāĻ¨ā§āϏāĻĢāĻžāϰ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻŦā§āϝāĻŦāĻšāĻžāϰāĻ•āĻžāϰ⧀āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āϤ⧈āϰāĻŋ āϏāĻšāĻžā§ŸāϤāĻž āϕ⧇āĻ¨ā§āĻĻā§āϰāϤ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻžāĻŦāϞ⧀ āĻ…āύ⧁āϏāϰāĻŖ āĻ•āϰ⧇ āϝ⧇āϏāĻŦ eReader-āĻ āĻĢāĻžāχāϞ āĻĒāĻĄāĻŧāĻž āϝāĻžāĻŦ⧇ āϏ⧇āĻ–āĻžāύ⧇ āĻŸā§āϰāĻžāĻ¨ā§āϏāĻĢāĻžāϰ āĻ•āϰ⧁āύāĨ¤